Table 3.
Prognostic factors for overall survival (OS), progression-free survival (PFS), and hepatic PFS (hPFS)
| Category | Median (95% CI) | p-value | HR (95% CI) | p-value HR | |
|---|---|---|---|---|---|
| Overall survival | |||||
| Position of TARE in the continuum of care | 1st line TARE | 16.2 (9.0–27.2) | 0.0028 | ||
| 1st line TARE plus CT | 32.5 (11.8–27.0) | 0.64 (0.34–1.22) | 0.1730 | ||
| 2nd line TARE | 12.0 (8.2–20.8) | 1.28 (0.82–2.02) | 0.2817 | ||
| > 2nd line TARE | 9.3 (4.5–14.7) | 2.37 (1.31–4.29) | 0.0042 | ||
| Extrahepatic disease prior to TARE | No | 18.4 (11.8–22.9) | 0.0023 | 0.55 (0.37–0.81) | 0.0026 |
| Yes | 10.9 (6.2–14.7) | ||||
| Cirrhosis | No | 16.6 (13.2–21.1) | 0.0051 | 0.47 (0.28–0.81) | 0.0062 |
| Yes | 7.7. (3.8–10.0) | ||||
| Dose methodology | BSA/mBSA | 12.0 (9.4–16.6) | 0.0363 | 0.67 (0.46–0.98) | 0.0379 |
| Partition model | 17.1 (10.1–26.2) | ||||
| Locoregional treatments after TARE | No | 11.8 (9.7–16.6) | 0.0101 | 1.98 (1.17–3.37) | 0.0116 |
| Yes | 27.7 (16.2–37.0) | ||||
| Systemic therapy after TARE | No | 9.3 (7.0–14.0) | 0.0008 | 1.87 (1.29–2.71) | 0.0010 |
| Yes | 20.6 (14.7–26.2) | ||||
| Additional treatments after TARE | No | 8.2 (5.7–11.2) | 0.0000 | 2.36 (1.62–3.43) | 0.0000 |
| Yes | 20.8 (15.4–27.7) | ||||
| Progression-free survival | |||||
| Position of TARE in the continuum of care | 1st line TARE | 7.4 (3.9–11.0) | 0.0012 | ||
| 1st line TARE plus CT | 11.3 (6.1–14.0) | 0.80 (0.46–1.40) | 0.4405 | ||
| 2nd line TARE | 5.1 (3.1–6.4) | 1.56 (1.04–2.33) | 0.0300 | ||
| > 2nd line TARE | 3.5 (2.5–4.3) | 2.36 (1.39–4.04) | 0.0016 | ||
| Extrahepatic disease prior to TARE | No | 6.9 (5.2–8.6) | 0.0025 | 0.59 (0.42–0.83) | 0.0028 |
| Yes | 3.6 (3.0–6.0) | ||||
| Time from diagnosis to treatment | < 6.1 | 7.5 (5.3–10.2) | 0.0054 | 1.59 (1.15–2.22) | 0.0057 |
| > = 6.1 | 4.4 (3.8–6.2) | ||||
| Total tumour to liver (%) | < 10% | 7.3 (4.4–12.0) | 0.0602 | ||
| 10–20% | 7.1 (4.4–9.3) | 1.44 (0.89–2.34) | 0.1414 | ||
| > 20% | 4.4 (3.5–7.0) | 1.74 (1.09–2.80) | 0.0210 | ||
| Hepatic progression-free survival | |||||
| Position of TARE in the continuum of care | 1st line TARE | 7.5 (4.3–11.0) | 0.0005 | ||
| 1st line TARE plus CT | 13.8 (8.3–28.1) | 0.63 (0.35–1.12) | 0.1140 | ||
| 2nd line TARE | 5.7 (3.8–7.2) | 1.54 (1.03–2.30) | 0.0337 | ||
| > 2nd line TARE | 3.9 (2.6–5.7) | 2.15 (1.27–3.67) | 0.0047 | ||
| Extrahepatic disease prior to TARE | No | 7.4 (5.7–9.3) | 0.0032 | 0.60 (0.42–0.84) | 0.0035 |
| Yes | 5.0 (3.1–6.4) | ||||
| Time from diagnosis to treatment | < 6.1 | 8.6 (6.1–10.7) | 0.0021 | 1.68 (1.20–2.35) | 0.0023 |
| > = 6.1 | 5.7 (4.0–7.1) | ||||
Cox model, p-value 0.05. Only variables with a p < 0.05 are shown here. A complete overview of the outcomes of the univariable analyses for OS, PFS and hPFS can be found in supplements 4–6
Levels of significance: p < 0.05 (Log-rank test [Mantel–Haenszel version]). The following variables were considered: Gender; ECOG; Extrahepatic disease prior to treatment; Location of liver tumors; Ascites; Cirrhosis; Prior surgery; Dose methodology; Treatment intention; Prior locoregional treatments; Locoregional treatments after TARE; Systemic therapy after TARE; Additional treatments after TARE; Time from diagnosis to treatment (months); Total tumour to liver (%); Right tumour to liver (%); Left tumour to liver (%); ALBI grade and International Normalized Ratio
ALBI albumin-bilirubin, BSA body surface area, CI confidence interval, CT concomitant treatment, ECOG Eastern Cooperative Oncology Group, ICC intrahepatic cholangiocarcinoma, HR hazard ratio, TARE transarterial radioembolization